Search Result

Results for "

CSFs

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (1) Amyloid-β (2) Apoptosis (7) Aurora Kinase (1) Autophagy (1) Bacterial (1) Bcr-Abl (1) Beta-secretase (2) Biochemical Assay Reagents (1) c-Fms (84) c-Kit (11) COX (2) Discoidin Domain Receptor (1) ERK (2) Farnesyl Transferase (1) Fatty Acid Synthase (FASN) (1) FGFR (5) FLT3 (3) Fungal (1) Glutathione Peroxidase (1) HIF/HIF Prolyl-Hydroxylase (2) Histamine Receptor (1) Interleukin Related (5) JAK (1) Leukotriene Receptor (2) Liposome (1) MEK (1) Mitochondrial Metabolism (1) PDGFR (8) Phosphatase (1) Raf (2) RANKL/RANK (1) Ras (2) Reactive Oxygen Species (1) SARS-CoV (3) Ser/Thr Kinase (1) Small Interfering RNA (siRNA) (15) Src (3) STAT (3) TAM Receptor (4) Tie (1) TNF Receptor (2) Transmembrane Glycoprotein (1) TREM receptor (1) VEGFR (8) γ-secretase (2)
By Research Areas:	Cancer (72) Cardiovascular Disease (4) Infection (3) Inflammation/Immunology (45) Metabolic Disease (6) Neurological Disease (15)
Oligonucleotides:	Rat Pre-designed siRNA Sets (1) Mouse Pre-designed siRNA Sets (7) Cationic Lipids (1) Human Pre-designed siRNA Sets (7) siRNAs (15)

133

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-109052

Atabecestat JNJ-54861911	Beta-secretase	Neurological Disease
Atabecestat (JNJ-54861911) is a potent brain-penetrant and orally active β-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitor, achieves robust and high CSF Aβ reduction. Atabecestat s tolerated and displays a sustained pharmacokinetic (PK) and pharmacodynamic (PD) characteristics. Atabecestat has the potential for Alzheimer's Disease treatment .

HY-125393

Leustroducsin A	c-Fms	Cancer
Leustroducsin A is a colony-stimulating factor (CSF) inducer. Leustroducsin A induces production of CSF by bone marrowstromal cells .

HY-125377

Leustroducsin C	c-Fms	Cancer
Leustroducsin C is a colony-stimulating factor (CSF) inducer. Leustroducsin C induces production of CSF by bone marrowstromal cells .

HY-125086

Leustroducsin B LSN-B	c-Fms	Cardiovascular Disease
Leustroducsin B is a colony-stimulating factor (CSF) inducer. Leustroducsin B induces CSF production in bone marrow stromal cells .

HY-122767

Romurtide Muroctasin	Interleukin Related	Inflammation/Immunology
Romurtide (Muroctasin), a synthetic muramyl dipeptide derivative, is a cytokines inducer. Romurtide can increase peripheral neutrophils and monocytes in vivo and enhance production of colony-stimulating factors (CSFs), IL-1 and IL-6 in vitro .

HY-12938

AMG-8718	Beta-secretase	Neurological Disease
AMG-8718 is a potent, selective and orally active BACE1 inhibitor with IC₅₀ values of 0.0007, 0.005 µM for BACE1 and BACE2, respectively. AMG-8718 significantly decreases Aβ₄₀ levels in the CSF and brain .

HY-162309

CSF1R-IN-20	c-Fms	Cancer
CSF1R-IN-20 (compound 7a) is a *CSF-1R* Inhibitor with an IC₅₀ value of 467 nM. CSF1R-IN-20 inhibits CSF-1R auto-phosphorylation .

HY-144042

CSF1R-IN-6	c-Fms	Cancer
CSF1R-IN-6 is a potent inhibitor of *CSF1R. CSF-1R is expressed in macrophages, and the survival and differentiation of macrophages depends on the CSF-1/CSF-1R signaling pathway. CSF1R-IN-6 affects the exchange of inflammatory factors between TAMs and glioma cells. CSF*1R-IN-6 has the potential for the research of cancer disease (extracted from patent WO2021197276A1, compound 5) .

HY-144041

CSF1R-IN-5	c-Fms	Cancer
CSF1R-IN-5 is a potent inhibitor of *CSF1R. CSF-1R is expressed in macrophages, and the survival and differentiation of macrophages depends on the CSF-1/CSF-1R signaling pathway. CSF1R-IN-5 affects the exchange of inflammatory factors between TAMs and glioma cells. CSF*1R-IN-5 has the potential for the research of cancer disease (extracted from patent WO2021197276A1, compound 11) .

HY-144040

CSF1R-IN-4	c-Fms	Cancer
CSF1R-IN-4 is a potent inhibitor of *CSF1R. CSF-1R is expressed in macrophages, and the survival and differentiation of macrophages depends on the CSF-1/CSF-1R signaling pathway. CSF1R-IN-4 affects the exchange of inflammatory factors between TAMs and glioma cells. CSF*1R-IN-4 has the potential for the research of cancer disease (extracted from patent WO2021197276A1, compound 104) .

HY-157996

CSF1R-IN-21	c-Fms	Neurological Disease
CSF1R-IN-21 (compound 7e) is a *CSF-1R* Inhibitor with an IC₅₀ value of 31 nM. CSF1R-IN-21 inhibits *CSF-1R* auto-phosphorylation and can be used for the research of neurodegenerative diseases .

HY-147608

CSF1R-IN-7	c-Fms	Neurological Disease
CSF1R-IN-7 (Formula I) is a *CSF-1R* inhibitor. CSF1R-IN-7 can be used for Alzheimer’s disease research .

HY-157422

CSF1R-IN-19	c-Fms	Cancer
CSF1R-IN-19 is a potent inhibitor of *CSF1R. CSF1R-IN-19 affects the exchange of inflammatory factors between TAMs and glioma cells. CSF*1R-IN-19 has the potential for the research of cancer .

HY-147617

CSF1R-IN-14	c-Fms	Cancer
CSF1R-IN-14 is an isoindolinone derivative compound. CSF1R-IN-14 is a potent inhibitor of *CSF1R. Colony stimulating factor 1 (CSF-1, also known as macrophage colony stimulating factor, M-CSF) is an important growth factor that controls bone marrow progenitor cells, monocytes, macrophages, and giants. CSF*1R-IN-14 has the potential for the research of cancer diseases (extracted from patent WO2019134662A1, compound 1) .

HY-P99368

Lacnotuzumab MCS110	c-Fms	Metabolic Disease Cancer
Lacnotuzumab (MCS110) is a neutralizing humanized IgG1/κ monoclonal antibody targeting *CSF-1* that prevents CSF-1 from activating the CSF-1R. Lacnotuzumab can be used for the research of pigmented villonodular synovitis .

HY-147610

CSF1R-IN-9	c-Fms	Cancer
CSF1R-IN-9 (Compound 46) is a *CSF-1R* inhibitor with an IC₅₀ of 0.028 μM .

HY-147609

CSF1R-IN-8	c-Fms	Cancer
CSF1R-IN-8 (Compound 22) is a *CSF-1R* inhibitor with an IC₅₀ of 0.012 μM .

HY-147611

CSF1R-IN-10	c-Fms	Cancer
CSF1R-IN-10 (Compound 48) is a *CSF-1R* inhibitor with an IC₅₀ of 0.005 μM .

HY-158363

CSF1R-IN-25	c-Fms	Neurological Disease Inflammation/Immunology Cancer
CSF1R-IN-25 (compound 36) is an orally effective *CSF1R* inhibitor. CSF1R-IN-25 can be used to study cancer, inflammation, and neurodegeneration .

HY-147615

CSF1R-IN-12	c-Fms	Cancer
CSF1R-IN-12 is a potent inhibitor of *CSF1R. Colony stimulating factor 1 (CSF-1, also known as macrophage colony stimulating factor, M-CSF) is an important growth factor that controls bone marrow progenitor cells, monocytes, macrophages, and giants. CSF*1R-IN-12 has the potential for the research of cancer diseases (extracted from patent WO2019134661A1, compound 1) .

HY-147616

CSF1R-IN-13	c-Fms	Cancer
CSF1R-IN-13 is a potent inhibitor of *CSF1R. Colony stimulating factor 1 (CSF-1, also known as macrophage colony stimulating factor, M-CSF) is an important growth factor that controls bone marrow progenitor cells, monocytes, macrophages, and giants. CSF*1R-IN-13 has the potential for the research of cancer diseases (extracted from patent WO2019134661A1, compound 32) .

HY-155550

CSF1R-IN-17	c-Fms	Inflammation/Immunology
CSF1R-IN-17 (compound 9) is a potent and selective *CSF1R* antagonist, with an IC₅₀ of 0.2 nM. CSF1R-IN-17 can inhibit osteoclast differentiation .

HY-158148

CSF1R-IN-23	c-Fms	Neurological Disease Inflammation/Immunology
CSF1R-IN-23 (Compound 7dri) is a selective inhibitor for colony-stimulating factor-1 receptor (CSF1R), with IC₅₀ of 36.1 nM. CSF1R-IN-23 serves as antineuroinflammatory agent in mouse model. CSF1R-IN-23 is blood brain barrier (BBB) permeable .

HY-160842

CSF1R-IN-24	c-Fms	Neurological Disease
CSF1R-IN-24 (Example 134) is an orally active *CSF1R* inhibitor. CSF1R-IN-24 significantly inhibits the survival of human ipSC-derived microglia (hiPSC-MG) .

HY-P990381

*Anti-CSF2/GM-CSF* Antibody**	c-Fms	Inflammation/Immunology
The Anti-CSF2/GM-CSF Antibody is a CHO-expressed human antibody that targets *CSF2/GM-CSF. The Anti-CSF2/GM-CSF* Antibody has a huIgG1-type heavy chain and a huλ-type light chain, with a predicted molecular weight (MW) of 145.02 kDa. The isotype control for the Anti-CSF2/GM-CSF Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).

HY-168954

CSF1R-IN-26	c-Fms Apoptosis Akt ERK STAT	Inflammation/Immunology Cancer
CSF1R-IN-26 (Compound III-1) is the inhibitor for *CSF-1R* with an IC₅₀ of 20.07 nM. CSF1R-IN-26 promotes the polarization of M2 macrophages to M1 macrophages, thereby inducing apoptosis in MC-38 cancer cell. CSF1R-IN-26 inhibits the activation of AKT/ERK/STAT3 signaling pathway. CSF1R-IN-26 reconstructs the tumor immune microenvironment and exhibits antitumor activity in mouse models. CSF1R-IN-26 exhibits pharmacokinetics characteristics in SD rats with a half-life 1.86 hours, and an oral bioavailability of 79.22% .

HY-112451

cFMS Receptor Inhibitor II	c-Fms	Inflammation/Immunology
cFMS Receptor Inhibitor II is a *CSF1R* kinase inhibitor. CSF-1 is a cytokine .

HY-101774

CSF1R-IN-1 1 Publications Verification	c-Fms	Cancer
CSF1R-IN-1 is a *CSF1R* inhibitor with an with an IC₅₀ of 0.5 nM.

HY-155001

CSF1R-IN-15	c-Fms	Others
CSF1R-IN-15 (compound 23) is an inhibitor targeting *CSF1R. The colony-stimulating factor-1 receptor (CSF1R) is a tyrosine kinase embedded in the cell membrane of macrophages. The receptor is activated by colony-stimulating factor-1 (CSF-1) and interleukin-34, and signaling via CSF*1R is crucial for the differentiation, proliferation, and survival of macrophages .

HY-139990

CSF1R-IN-3	c-Fms	Cancer
CSF1R-IN-3 (compound 21) is a potent and orally active *CSF-1R* inhibitor (IC₅₀=2.1 nM). CSF1R-IN-3 is a potent antiproliferative activity against colorectal cancer cells. CSF1R-IN-3 inhibits the progression of colorectal cancer by suppressing the migration of macrophages, reprograming M2-like macrophages to the M1 phenotype, and enhancing the antitumor immunity .

HY-161084

CSF1R-IN-18	c-Fms	Neurological Disease Cancer
CSF1R-IN-18 (Compdound 16t), para-aniline derivative, is a colony-stimulating factor 1 receptor (CSF1R) inhibitor. CSF1R-IN-18 can be used for the research of cancers, CNS-diseases and bone diseases .

HY-162415

CSF1R-IN-22	c-Fms Apoptosis	Cancer
CSF1R-IN-22 (Compound C19) is an orally effective *CSF-1R* selective inhibitor (IC₅₀<6 nM). CSF1R-IN-22 enhances the secretion of CXCL9 from M2 macrophages, increases CD8 ⁺ T cell infiltration. CSF1R-IN-22 boosts anti-tumor immune responses of anti-PD-1, and induces apoptosis in tumor cells. CSF1R-IN-22 can effectively reprogram M2-like TAMs (tumor-associated macrophages) to the M1 phenotype and reshape the TME by inducing the recruitment of CD8 ⁺ T cells into tumors and reducing the infiltration of immunosuppressive Tregs and MDSCs .

HY-P99245

Emactuzumab RG 7155; RO 5509554	c-Fms	Cancer
Emactuzumab(RG 7155) is a specific monoclonal antibody that inhibits colonystimulating factor 1 receptor *(CSF1R)* activation. Emactuzumab has high affinity for CSF-1R with K_i value of 0.2 nM to blocks CSF-1R dimerization. Emactuzumab can be used for the research of several diseases, such as diffuse-type tenosynovial giant cell tumour (dt-GCT) .

HY-117244

AZD7507 1 Publications Verification	c-Fms	Cancer
AZD7507 is a potent and orally active *CSF-1R* inhibitor, with antitumor activity.

HY-P99207

Lenzilumab KB 003	SARS-CoV	Cancer
Lenzilumab (KB 003) is a human monoclonal antibody targeting *CSF2/GM-CSF* for COVID-19, chronic myelomonocytic leukemia (CMML) and juvenile myelomonocytic leukemia (JMML) studies .

HY-159503A

Segigratinib hydrochloride 3D185; HH185	FGFR c-Fms	Cancer
Segigratinib hydrochloride (3D185) is a potent inhibitor of FGFR1/2/3 and *CSF-1R; The IC₅₀* values for FGFR1, FGFR2, FGFR3 and CSF-1R are 0.5, 1.3, 3.6 and 3.8 nM, respectively. Segigratinib hydrochloride has antitumor activity .

HY-P99795

Otilimab GSK 3196165; MOR103	c-Fms	Inflammation/Immunology
Otilimab (GSK 3196165) is an anti-granulocyte-macrophage colony-stimulating factor (GM-CSF) human monoclonal antibody. Otilimab neutralises the biological function of GM-CSF by blocking the interaction of GM-CSF with its cell surface receptor .

HY-P99134

*Anti-Mouse GM-CSF* Antibody (MP1-22E9)**	c-Fms	Inflammation/Immunology
Anti-Mouse GM-CSF Antibody is an anti-mouse GM-CSF IgG2a antibody inhibitor derived from host Rat.

HY-153277

*Axl/Mer/CSF1R-IN-2*	TAM Receptor c-Fms	Neurological Disease
Axl/Mer/CSF1R-IN-2 (Comp 4) is a Axl, Mer and *CSF1R* inhibitor .

HY-P99031

Mavrilimumab CAM 3001	c-Fms	Cardiovascular Disease Inflammation/Immunology
Mavrilimumab (CAM 3001) is a monoclonal antibody that binds to the α subunit of the granulocyte-macrophage colony stimulating factor (GM-CSF) receptor and blocks intracellular signalling downstream of GM-CSF. GM-CSF might be a mediator of the hyperactive inflammatory response associated with respiratory failure and death .

HY-P990043

Iluzanebart	Ser/Thr Kinase TREM receptor	Inflammation/Immunology
Iluzanebart is a human monoclonal IgG1 antibody and is the agonist antibody for human TREM2 (hTREM2). Iluzanebart improves the survival and function of microglia by activating the TREM2 signaling pathway to compensate for the loss of CSF1R function. Iluzanebart can be used for research of adult-onset leukoencephalopathy associated with CSF1R (colony stimulating factor 1 receptor) (CSF1R-ALSP) .

HY-101526

GENZ-882706 RA03546849	c-Fms	Inflammation/Immunology
GENZ-882706 is a potent colony stimulating factor-1 receptor (CSF-1R) Inhibitor extracted from patent WO 2017015267A1.

HY-P990125

*Anti-Mouse (CSF1R/CD115) Antibody (AFS98)*	c-Fms	Others
Anti-Mouse CSF1R (CD115) Antibody (AFS98) is a rat-derived IgG2a, κ type antibody inhibitor, targeting to mouse CSF1R.

HY-RS03227

CSF1 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
CSF1 Human Pre-designed siRNA Set A contains three designed siRNAs for CSF1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

CSF1 Human Pre-designed siRNA Set A CSF1 Human Pre-designed siRNA Set A

HY-RS16951

Csf3 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)
Csf3 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Csf3 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Csf3 Mouse Pre-designed siRNA Set A Csf3 Mouse Pre-designed siRNA Set A

HY-RS03231

CSF2 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
CSF2 Human Pre-designed siRNA Set A contains three designed siRNAs for CSF2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

CSF2 Human Pre-designed siRNA Set A CSF2 Human Pre-designed siRNA Set A

HY-RS16786

Csf2 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)
Csf2 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Csf2 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Csf2 Mouse Pre-designed siRNA Set A Csf2 Mouse Pre-designed siRNA Set A

HY-112446

ST638	Others	Inflammation/Immunology
ST638 is a potent tyrosine kinase inhibitor (IC₅₀=370 nM). ST638 also targets the CSF-1 receptor and inhibits PGE2 production .

HY-RS16853

Csf1 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)
Csf1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Csf1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Csf1 Mouse Pre-designed siRNA Set A Csf1 Mouse Pre-designed siRNA Set A

HY-RS03234

CSF3 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
CSF3 Human Pre-designed siRNA Set A contains three designed siRNAs for CSF3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

CSF3 Human Pre-designed siRNA Set A CSF3 Human Pre-designed siRNA Set A

Cat. No.	Product Name

HY-L161

Cytokine Inhibitors Library

997 compounds

Cytokines are a kind of low molecular soluble proteins synthesized and secreted by immunogen, mitogen or other factors. They have functions of regulating innate and adaptive immune responses, promoting hematopoiesis, stimulating cell activation, proliferation and differentiation. The process of releasing a large number of cytokines is also called “Cytokine storm”, which can cause damage to many tissues and organs in the body. Cytokine is involved in the pathogenesis of many human diseases, including cancer, diabetes, chronic inflammatory diseases and so on. Cytokine inhibitors are a class of essential compounds that act by directly inhibiting the synthesis and release of cytokine or blocking the binding of cytokine to their receptors. Cytokine inhibitors are important compounds for the study of tumor and autoimmune diseases.

MCE designs a unique collection of 997 cytokine inhibitors, mainly targeting the receptor interleukin (IL), colony-stimulating factor (CSF), interferon (IFN), tumor necrosis factor (TNF), growth factor (GF) and chemokine, which is an effective tool for development and research of anti-cancer, anti-chronic inflammatory diseases and anti-autoimmune diseases compounds.

Cat. No.	Product Name	Type

HY-139410

Sodium caseinates	Cell Assay Reagents
Sodium caseinates, the salt of casein, are the main milk protein. Sodium caseinate are able to induce proliferation and activation of granulocytes as well as increase the serum concentration of two key cytokines, GM-CSF and G-CSF. Sodium caseinate induces mouse granulopoiesis .

HY-151508

Diamino lipid DAL4	Drug Delivery
Diamino lipid DAL4 is diamino lipid for the preparation of lipid nanoparticles (LNPs) encapsulated with mRNAs encoding cytokines including IL-12, IL-27 and GM-CSF. Diamino lipid DAL4 delivers mRNA to tumor cells to exert anti-tumor activity .

Cat. No.	Product Name	Target	Research Area

HY-106228

HLF1-11	Fungal Bacterial Glutathione Peroxidase	Infection
HLF1-11, a human lactoferrin-derived peptide, is a broad spectrum antimicrobial agent. HLF1-11 inhibits human MPO activity. HLF1-11 also directs GM-CSF-driven monocyte differentiation toward macrophages, and enhances immune responses .

HY-122767

Romurtide Muroctasin	Interleukin Related	Inflammation/Immunology
Romurtide (Muroctasin), a synthetic muramyl dipeptide derivative, is a cytokines inducer. Romurtide can increase peripheral neutrophils and monocytes in vivo and enhance production of colony-stimulating factors (CSFs), IL-1 and IL-6 in vitro .

HY-P1111A

Lyn peptide inhibitor TFA	Src Interleukin Related	Inflammation/Immunology
Lyn peptide inhibitor TFA is a potent and cell-permeable inhibitor of Lyn-coupled IL-5 receptor signaling pathway, while keeping other signals intact. Lyn peptide inhibitor TFA blocks Lyn activation and inhibits the binding of Lyn tyrosine kinase to βc subunit of IL-3/GM-CSF/IL-5 receptors. Lyn peptide inhibitor TFA can be used for study of asthma, allergic, and other eosinophilic disorders .

Cat. No.	Product Name	Target	Research Area

HY-P99368

Lacnotuzumab MCS110	c-Fms	Metabolic Disease Cancer
Lacnotuzumab (MCS110) is a neutralizing humanized IgG1/κ monoclonal antibody targeting *CSF-1* that prevents CSF-1 from activating the CSF-1R. Lacnotuzumab can be used for the research of pigmented villonodular synovitis .

HY-P99245

Emactuzumab RG 7155; RO 5509554	c-Fms	Cancer
Emactuzumab(RG 7155) is a specific monoclonal antibody that inhibits colonystimulating factor 1 receptor *(CSF1R)* activation. Emactuzumab has high affinity for CSF-1R with K_i value of 0.2 nM to blocks CSF-1R dimerization. Emactuzumab can be used for the research of several diseases, such as diffuse-type tenosynovial giant cell tumour (dt-GCT) .

HY-P99207

Lenzilumab KB 003	SARS-CoV	Cancer
Lenzilumab (KB 003) is a human monoclonal antibody targeting *CSF2/GM-CSF* for COVID-19, chronic myelomonocytic leukemia (CMML) and juvenile myelomonocytic leukemia (JMML) studies .

HY-P99795

Otilimab GSK 3196165; MOR103	c-Fms	Inflammation/Immunology
Otilimab (GSK 3196165) is an anti-granulocyte-macrophage colony-stimulating factor (GM-CSF) human monoclonal antibody. Otilimab neutralises the biological function of GM-CSF by blocking the interaction of GM-CSF with its cell surface receptor .

HY-P99134

*Anti-Mouse GM-CSF* Antibody (MP1-22E9)**	c-Fms	Inflammation/Immunology
Anti-Mouse GM-CSF Antibody is an anti-mouse GM-CSF IgG2a antibody inhibitor derived from host Rat.

HY-P99031

Mavrilimumab CAM 3001	c-Fms	Cardiovascular Disease Inflammation/Immunology
Mavrilimumab (CAM 3001) is a monoclonal antibody that binds to the α subunit of the granulocyte-macrophage colony stimulating factor (GM-CSF) receptor and blocks intracellular signalling downstream of GM-CSF. GM-CSF might be a mediator of the hyperactive inflammatory response associated with respiratory failure and death .

HY-P990257

*Anti-Mouse CSF1 Antibody (5A1)*	Inhibitory Antibodies	Others
Anti-Mouse CSF1 Antibody (5A1) is a rat-derived IgG1, κ type antibody inhibitor, targeting to mouse CSF1.

HY-P990384

*Anti-CSF3R/G-CSFR Antibody*	Inhibitory Antibodies	Inflammation/Immunology
Anti-CSF3R/G-CSFR Antibody is a CHO-expressed human antibody that targets *CSF3R/G-CSFR. Anti-CSF3R/G-CSFR Antibody contains huIgG4SP heavy chain and huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-CSF*3R/G-CSFR Antibody can be referenced as Human IgG4 kappa, Isotype Control (HY-P99003).

HY-P990381

*Anti-CSF2/GM-CSF* Antibody**	c-Fms	Inflammation/Immunology
The Anti-CSF2/GM-CSF Antibody is a CHO-expressed human antibody that targets *CSF2/GM-CSF. The Anti-CSF2/GM-CSF* Antibody has a huIgG1-type heavy chain and a huλ-type light chain, with a predicted molecular weight (MW) of 145.02 kDa. The isotype control for the Anti-CSF2/GM-CSF Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).

HY-P990963

Albipagrastim alfa	Inhibitory Antibodies	Inflammation/Immunology
HY-P990963 is an *CSF3R*-targeting human antibody .

HY-P990043

Iluzanebart	Ser/Thr Kinase TREM receptor	Inflammation/Immunology
Iluzanebart is a human monoclonal IgG1 antibody and is the agonist antibody for human TREM2 (hTREM2). Iluzanebart improves the survival and function of microglia by activating the TREM2 signaling pathway to compensate for the loss of CSF1R function. Iluzanebart can be used for research of adult-onset leukoencephalopathy associated with CSF1R (colony stimulating factor 1 receptor) (CSF1R-ALSP) .

HY-P990125

*Anti-Mouse (CSF1R/CD115) Antibody (AFS98)*	c-Fms	Others
Anti-Mouse CSF1R (CD115) Antibody (AFS98) is a rat-derived IgG2a, κ type antibody inhibitor, targeting to mouse CSF1R.

HY-P990849

*Anti-CSF1R/CD115 Antibody (2-4A5-4)*	Inhibitory Antibodies	Others
Anti-CSF1R/CD115 Antibody (2-4A5-4) is a kind of rat IgG1, κ chimeric antibody, targeting to human *CSF1R/CD115. The recommend isotype control of Anti-CSF*1R/CD115 Antibody (2-4A5-4): Rat IgG1 kappa, Isotype Control (HY-P99979).

HY-P99307

Namilumab AMG-203; Anti-Human CSF2 Recombinant Antibody	c-Fms	Inflammation/Immunology
Namilumab (AMG203) is a human IgG1 monoclonal antibody that binds with high affinity to the *GM-CSF* ligand*, potently neutralizing GM-CSF*. Namilumab can be used for the research of rheumatoid arthritis .

HY-P991048

AMG-820	c-Fms	Cancer
AMG-820 is a fully human IgG2 antibody that targets CSF-1R. AMG-820 inhibits binding of the ligands CSF1 and IL34 and subsequent ligand-induced receptor activation. The isotype control for AMG-820 can refer to Human IgG2 kappa, Isotype Control (HY-P99002) .

HY-P99452

Axatilimab SNDX-6352	c-Fms	Inflammation/Immunology Cancer
Axatilimab (SNDX-6352) is a humanized IgG4 antibody with high affinity to *CSF-1R*. Axatilimab can be used for the research of chronic graft versus host disease (cGVHD) and neoplastic diseases .

HY-P990094

Trabikibart CSL311	c-Fms	Inflammation/Immunology
Trabikibart (CSL311), a βc (CSF2RB)-specific, fully human monoclonal antibody, binds to a unique epitope that is specific to the cytokine-binding site of the human βc receptor. Trabikibart has picomolar binding affinity for the human βc receptor. Trabikibart is a potent inhibitor of the combined effects of IL-3, GM-CSF and IL-5 on the survival of eosinophils. Trabikibart has the potential for chronic inflammatory diseases research .

HY-P990975

Birinkibart	Transmembrane Glycoprotein	Inflammation/Immunology
HY-P990975 is an *CSF2RB*-targeting IgG4κ type human antibody, the recommed isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .

HY-P99913

Eflapegrastim	c-Fms	Inflammation/Immunology Cancer
Eflapegrastim is a human IgG4 monoclonal antibody, is also a granulocyte colony-stimulating factor (G-CSF). Eflapegrastim targets to *G-CSF* receptor (c-Fms**). Eflapegrastim stimulates proliferation and differentiation of neutrophil progenitor cells and maintains stable numbers of mature and functional neutrophils. Eflapegrastim also shortens the duration of neutropenia .

HY-P99879

Efbemalenograstim alfa Benegrastim; Bineuta; F 627	Inhibitory Antibodies	Inflammation/Immunology Cancer
Efbemalenograstim alfa (F 627) is a recombinant fusion protein. Efbemalenograstim alfa is a long acting dimeric granulocyte colony-stimulating factor (G-CSF) that contains two human G-CSF fused to a human immunoglobulin G2 (hIgG2)-Fc fragment with a peptide linker. Efbemalenograstim alfa induces the production of white blood cells .

HY-P990619

LY3022855	Inhibitory Antibodies	Inflammation/Immunology
LY3022855 is a CHO-expressed human antibody that targets *CSF1R/M-CSFR/CD115*. LY3022855 has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for LY3022855 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).

HY-P99779

Plonmarlimab TJ003234; TJM2	c-Fms SARS-CoV	Infection Inflammation/Immunology
Plonmarlimab (TJ003234) is an anti-GM-CSF monoclonal antibody. Plonmarlimab can be used for research of rheumatoid arthritis and COVID-19 .

HY-P99642

Gimsilumab MORAb-022	c-Fms SARS-CoV	Infection Inflammation/Immunology
Gimsilumab (MORAb-022) is a human anti-GM-CSF monoclonal antibody. Gimsilumab has the potential for the research of COVID-19 and rheumatoid arthritis (RA) .

HY-P99440

Anumigilimab CSL-324	c-Fms JAK STAT	Inflammation/Immunology
Anumigilimab (CSL-324) is an human IgG4 mAb against human *granulocyte colony-stimulating factor (G-CSF) receptor*. Anumigilimab can be used for increasing numbers of neutrophils at sites of inflammation .

HY-P99458

Balugrastim CG 10639	c-Fms	Cancer
Balugrastim (CG 10639) is a novel long-acting recombinant granulocyte colony-stimulating factor (G-CSF) obtained by means of a genetic fusion between recombinant human serum albumin and granulocyte colony-stimulating factor. Balugrastim can be used for the research of breast cancer .

HY-P9933

Dinutuximab APN-311	Inhibitory Antibodies	Cancer
Dinutuximab (Unituxin; APN-311) is a chimeric, human-murine, anti-GD2 monoclonal antibody. Dinutuximab potently enlongs event-free survival and overall survival, in high-risk neuroblastoma treatment, in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), aldesleukin (interleukin-2 [IL-2]), and isotretinoin (13-cis-retinoic acid [RA]) .

HY-P99259

Cabiralizumab FPA 008; Anti-Human CSF1R Recombinant Antibody	c-Fms	Inflammation/Immunology Cancer
Cabiralizumab (FPA 008) is an anti-CSF1R monoclonal antibody (MAb). Cabiralizumab enhances T cell infiltration and antitumor T cell immune responses. Cabiralizumab inhibits the activation of osteoclasts and blocks bone destruction, and can be used in the research of rheumatoid arthritis (RA). Cabiralizumab can combine with Nivolumab (HY-P9903) for lung cancer research .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks